News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Congress Makes Sovaldi A Scapegoat: The Cost-Innovation Paradox In The U.S. Healthcare System


3/27/2014 7:25:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Last week, three senior members of the House Energy and Commerce Committee caused quite a kerfuffle in the investment community by sending biotech giant Gilead Sciences GILD -0.34% a letter demanding management justify the $84,000 price tag for Sovaldi (sofosbuvir), a recently-approved treatment for chronic hepatitis C (HCV). Sellside notes speculated that generalist investors, after an indiscriminate buying spree this year that further inflated already frothy biotech valuations, were fleeing the sector en masse and without apparent irony for the safety of bank and credit card stocks.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes

comments powered by Disqus
Forbes
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES